Ecog Performance Status Calculator
Score patient functional status using the Eastern Cooperative Oncology Group scale. Enter values for instant results with step-by-step formulas.
Calculator
Adjust values & calculateGenerally eligible for most clinical trials
Candidate for standard-dose chemotherapy, immunotherapy, and combination regimens
Formula
The ECOG Performance Status is a clinician-assessed ordinal scale from 0 (fully active) to 5 (dead). It evaluates the patient ability to perform daily activities, capacity for self-care, and proportion of time spent in bed or chair. Additional factors like weight loss percentage and symptom burden inform the comprehensive functional assessment.
Last reviewed: January 2026
Worked Examples
Example 1: ECOG 1 Patient - Clinical Trial Eligibility
Example 2: ECOG 3 Patient - Treatment Limitations
Background & Theory
The Ecog Performance Status Calculator applies the following established principles and formulas. Health and medicine calculators are grounded in validated physiological measurement methods established through decades of clinical research. Body Mass Index, or BMI, is calculated by dividing weight in kilograms by height in meters squared (kg/m²), a formula originating from Adolphe Quetelet's 19th-century statistical work and later codified by the WHO into standard classifications: underweight below 18.5, normal weight 18.5 to 24.9, overweight 25 to 29.9, and obese at 30 and above. Basal Metabolic Rate quantifies the minimum energy required to sustain life at rest. The Mifflin-St Jeor equation, published in 1990 and widely regarded as the most accurate for most adults, calculates BMR as (10 × weight in kg) + (6.25 × height in cm) − (5 × age) ± sex adjustment. The older Harris-Benedict equations, revised in 1984 by Roza and Shizgal, remain in common use. Total Daily Energy Expenditure is derived by multiplying BMR by a physical activity factor ranging from 1.2 for sedentary individuals to 1.9 for extremely active ones, following the methodology validated by doubly labeled water studies. Body fat percentage can be estimated without laboratory equipment using the U.S. Navy circumference method, which uses neck, waist, and hip measurements, or via BMI-derived equations adjusted for age and sex. The Jackson-Pollock skinfold method offers higher precision with calipers. Blood pressure classification, according to the American College of Cardiology and the 2017 ACC/AHA guidelines, defines normal as below 120/80 mmHg, elevated as 120 to 129 systolic, and hypertension stage 1 as 130 to 139 systolic or 80 to 89 diastolic. Target heart rate zones for aerobic exercise are derived from maximum heart rate estimates, most commonly using the formula 220 minus age in years, with moderate-intensity training typically defined as 50 to 70 percent of maximum heart rate and vigorous intensity at 70 to 85 percent, consistent with CDC and American Heart Association guidelines. These thresholds guide safe and effective cardiovascular conditioning.
History
The history behind the Ecog Performance Status Calculator traces back through the following developments. The history of health measurement stretches back to ancient Greece, where Hippocrates around 400 BCE laid the foundation for observational medicine by systematically recording patient symptoms, diet, and environment. His humoral theory, though scientifically superseded, established the principle that the body operates as an interconnected system subject to measurable imbalance. The transformation toward modern medicine accelerated in the 19th century. Louis Pasteur and Robert Koch developed germ theory in the 1860s and 1870s, identifying microorganisms as disease agents and enabling targeted interventions. Florence Nightingale, working during the Crimean War in the 1850s, introduced statistical analysis to nursing practice, demonstrating through data visualization that sanitation reduced mortality. Her work is foundational to evidence-based health measurement. The discovery of vitamins in the early 20th century, beginning with Casimir Funk's coinage of the term in 1912 and culminating in the isolation of vitamins A through K, created the field of nutritional science and gave rise to dietary reference intake frameworks. The World Health Organization, founded in 1948, subsequently established global standards for health metrics, disease classification through the International Classification of Diseases, and recommended daily allowances. The BMI as a clinical screening tool gained traction in the 1970s through Ancel Keys' large-scale epidemiological work, which validated Quetelet's index as a population-level obesity indicator. Through the 1980s and 1990s, the Framingham Heart Study produced landmark data linking cholesterol, blood pressure, and lifestyle factors to cardiovascular disease risk, directly shaping the numeric thresholds still used in health calculators. The evidence-based medicine movement, formalized by Gordon Guyatt and colleagues at McMaster University in the early 1990s, demanded that all health recommendations derive from systematically graded clinical evidence. The digital health era beginning in the 2000s brought these formulas to consumer devices, wearable sensors, and smartphone applications, expanding access to health self-monitoring on a global scale and enabling population-level data collection that continues to refine clinical reference ranges.
Frequently Asked Questions
Formula
ECOG PS = Clinician-assessed functional status grade (0-5)
The ECOG Performance Status is a clinician-assessed ordinal scale from 0 (fully active) to 5 (dead). It evaluates the patient ability to perform daily activities, capacity for self-care, and proportion of time spent in bed or chair. Additional factors like weight loss percentage and symptom burden inform the comprehensive functional assessment.
Worked Examples
Example 1: ECOG 1 Patient - Clinical Trial Eligibility
Problem: A 58-year-old with stage IIIB NSCLC can perform light office work but cannot do heavy lifting or gardening. He has lost 3% body weight over 6 months. Determine ECOG status and trial eligibility.
Solution: Patient is restricted in strenuous activity but ambulatory and can do sedentary work = ECOG 1\nWeight loss 3% = Low nutritional risk\nKPS equivalent = 70-80\nClinical trial eligibility: ECOG 0-1 required for most trials = Eligible
Result: ECOG 1 (Favorable prognosis). Eligible for most clinical trials. Candidate for standard combination chemotherapy.
Example 2: ECOG 3 Patient - Treatment Limitations
Problem: A 72-year-old with metastatic pancreatic cancer is confined to a recliner most of the day, needs help with bathing and meals, and has lost 12% body weight. Assess ECOG status and treatment options.
Solution: Limited self-care, confined to bed/chair >50% of waking hours = ECOG 3\nWeight loss 12% = High nutritional risk\nKPS equivalent = 30-40\nClinical trial eligibility: Generally not eligible
Result: ECOG 3 (Poor prognosis). Best supportive care recommended. Consider palliative care referral and goals of care discussion.
Frequently Asked Questions
What is the ECOG Performance Status scale?
The ECOG (Eastern Cooperative Oncology Group) Performance Status scale is a standardized measure of a cancer patient's functional capacity and ability to perform daily activities. Developed in 1982 by the ECOG cooperative group, it uses a simple 0-5 scoring system where 0 represents fully active status and 5 represents death. The scale was designed to provide an objective, reproducible assessment that could be used across clinical trials and clinical practice. ECOG PS is one of the most important prognostic factors in oncology, influencing treatment decisions, clinical trial eligibility, and survival predictions. It is also known as the WHO Performance Status or Zubrod scale, as these systems use identical criteria.
How does ECOG score affect treatment decisions?
ECOG Performance Status profoundly influences oncology treatment planning at every stage of care. Patients with ECOG 0-1 are generally candidates for aggressive treatment including combination chemotherapy, high-dose regimens, and most clinical trials. ECOG 2 patients may receive modified or reduced-intensity treatment, often single-agent chemotherapy or targeted therapy rather than intensive combinations. Patients with ECOG 3-4 are typically recommended for best supportive care and palliative treatments, as aggressive therapy is unlikely to provide benefit and may cause significant harm. Studies consistently show that patients with poor performance status have higher treatment-related mortality and shorter survival regardless of cancer type. Performance status often overrides tumor-specific factors in determining the appropriateness of systemic therapy.
What is the relationship between ECOG and Karnofsky Performance Status?
The ECOG and Karnofsky Performance Status (KPS) scales both measure patient functional capacity but use different scoring systems. KPS uses a 0-100 scale in increments of 10, while ECOG uses a simpler 0-5 scale. The approximate equivalences are: ECOG 0 equals KPS 90-100, ECOG 1 equals KPS 70-80, ECOG 2 equals KPS 50-60, ECOG 3 equals KPS 30-40, and ECOG 4 equals KPS 10-20. The ECOG scale is more commonly used in modern clinical trials because it is simpler and has less inter-observer variability. However, KPS provides finer granularity that can be useful for detecting subtle changes in patient function over time. Both scales are validated prognostic tools and can be converted between each other for comparison purposes.
How reliable is ECOG scoring between different physicians?
Inter-observer agreement for ECOG Performance Status is moderate, with kappa values typically ranging from 0.5 to 0.7 in published studies. Agreement is highest for extreme scores (ECOG 0 and ECOG 4) where functional status is clearly defined, and lowest for intermediate scores (ECOG 1-2) where the boundary between restricted activity and inability to work can be subjective. Studies have shown that oncologists tend to rate patients as having better performance status than nurses or patients themselves. Patient self-assessment often yields higher (worse) ECOG scores compared to physician assessment. To improve reliability, many institutions use structured interviews or standardized questionnaires. Training and calibration among raters can improve agreement, and some clinical trials require assessors to document specific functional activities rather than relying solely on global impression.
Does ECOG Performance Status predict survival?
ECOG Performance Status is one of the strongest independent prognostic factors for survival across virtually all cancer types. Multiple large meta-analyses have confirmed that each unit increase in ECOG score is associated with significantly worse overall survival. For example, in advanced non-small cell lung cancer, median survival for ECOG 0 patients is approximately 12-18 months, ECOG 1 is 8-12 months, and ECOG 2 is 4-6 months with standard chemotherapy. In pancreatic cancer, the survival difference between ECOG 0-1 and ECOG 2 can be three-fold or greater. Performance status remains prognostic even after adjusting for tumor stage, histology, and treatment received. This strong prognostic value is why ECOG PS is a mandatory stratification factor in most randomized oncology clinical trials and a critical element of treatment decision-making.
How often should ECOG Performance Status be reassessed?
ECOG Performance Status should be assessed at every clinical encounter in oncology practice, typically at each visit before chemotherapy cycles. The frequency depends on the clinical context and treatment phase. During active treatment, assessment at each cycle (every 2-4 weeks) is standard practice. During surveillance or maintenance therapy, monthly or quarterly assessment is appropriate. Performance status can change rapidly, especially with disease progression or treatment toxicity, making frequent reassessment essential. A decline in ECOG score may signal disease progression before imaging changes are apparent and should prompt clinical evaluation. Conversely, improvement in ECOG score after starting effective therapy is a positive prognostic sign. Documentation of serial ECOG scores creates a functional trajectory that helps guide ongoing treatment decisions and prognostic discussions.
References
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy